Palisade Bio Announces $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules
December 30, 2022 08:45 ET
|
Palisade Bio, Inc.
Carlsbad, CA, Dec. 30, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI)...
HOVERINK BIOTECHNOLOGIES INITIATES PRIVATE PLACEMENT OF CONVERTIBLE NOTES
April 27, 2018 21:22 ET
|
Hoverink Biotechnologies, Inc
LOS ANGELES, CA, April 27, 2018 (GLOBE NEWSWIRE) -- Hoverink Biotechnologies, Inc announced today it intends to offer, subject to market and other conditions, $2.5 million of Series A Convertible...